olivLaw · US equity research
Solésence, Inc. SLSN
Perfumes, Cosmetics & Other Toilet Preparations · SIC 2844 · Vertical: Perfumes, Cosmetics & Other Toilet Preparations (SIC 2844)
Solésence develops skin care products with mineral UV protection and sells active ingredients to other manufacturers, after its revenue grew in 2025 versus the prior year. In the second quarter of 2026 revenue fell to 15.3 million USD and the company reported a net loss of 158 thousand USD, so dependence on a few large customers is an important issue for investors.
At the close of 05 Nov 2026, Solésence, Inc. (SLSN) stock was 0.87 USD (−4.73% on the day), with market capitalisation 61.3 m USD, beta 1.18, 52-week range 0.64–3.08 USD. Latest reported quarter (Q2 2026): revenue of 15.3 m USD (−24.7% YoY), net income of -158.0 k USD (−104.9% YoY), diluted EPS 0.00 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 50.7
- neutral
- Bollinger (20, 2)
- 0.75 – 1.01
- in the lower half of the band · %B 0.44 · band width 29.6%
- SMA 50 / 200
- 0.86 / 1.07
- mixed trend
- MACD (12, 26, 9)
- -0.00 / -0.01
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +8.4% | −1.1% | +9.5 pp | — |
| 3 months | −15.8% | −0.5% | −15.4 pp | — |
| 6 months | −33.3% | +4.4% | −37.7 pp | — |
| Year to date | −45.8% | +12.3% | −58.1 pp | — |
| 1 year | −73.6% | +13.5% | −87.1 pp | +14.4% |
| 3 years | −6.8% | +76.4% | −83.2 pp | −16.3% |
| 5 years | −76.8% | +63.7% | −140.5 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 16.9 m | 12.6 m | 14.6 m | 20.4 m | 14.6 m | 12.5 m | 13.0 m | 15.3 m |
| Cost of revenue | 10.8 m | 9.8 m | 11.2 m | 13.9 m | 11.2 m | 9.0 m | 9.8 m | 10.6 m |
| Gross profit | 6.1 m | 2.8 m | 3.4 m | 6.4 m | 3.4 m | 3.4 m | 3.1 m | 4.7 m |
| Research & development | 970.0 k | 1.1 m | 1.0 m | 955.0 k | 1.1 m | 1.0 m | 1.0 m | 947.0 k |
| SG&A | 1.9 m | 1.9 m | 2.1 m | 3.0 m | 3.1 m | 2.2 m | 2.8 m | 3.7 m |
| Operating income | 3.2 m | -223.0 k | 256.0 k | 2.5 m | -781.0 k | 186.0 k | -700.0 k | 121.0 k |
| Depreciation & amortisation | 231.0 k ≈ | 228.0 k | 226.0 k | 225.0 k ≈ | 225.0 k ≈ | 221.0 k | 313.0 k | 323.0 k ≈ |
| Interest expense | 153.0 k | 108.0 k | 176.0 k | — | — | — | — | — |
| Pre-tax income | 3.0 m | -331.0 k | 80.0 k | 3.6 m | -1.1 m | -154.0 k | -962.0 k | -158.0 k |
| Income tax | — | — | — | 390.0 k | 0 ≈ | -317.0 k | — | — |
| Net income | 3.0 m | -558.0 k | 343.0 k | 3.2 m | -1.1 m | 163.0 k | -962.0 k | -158.0 k |
| Diluted EPS | 0.04 | -0.01 ≈ | 0.00 | 0.04 | -0.02 | 0.00 ≈ | -0.01 | 0.00 |
| Operating cash flow | 4.2 m ≈ | 2.2 m | -7.2 m | -654.0 k ≈ | -2.5 m ≈ | 1.8 m | 1.5 m | 191.0 k ≈ |
| Capex | 1.4 m ≈ | 2.6 m | — | — | — | — | — | — |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 14.2 m | 12.5 m | 17.1 m | 29.5 m | 37.3 m | 37.3 m | 52.3 m | 62.1 m |
| Revenue YoY | +13.8% | −11.9% | +36.9% | +72.1% | +26.6% | −0.1% | +40.4% | +18.6% |
| Net income | -2.1 m | -3.0 m | 989.0 k | 2.3 m | -2.6 m | -4.4 m | 4.2 m | 1.8 m |
| Net income YoY | unavailable | unavailable | unavailable | +134.6% | −213.1% | unavailable | unavailable | −57.7% |
| Diluted EPS | unavailable | -0.08 | 0.03 | 0.05 | -0.05 | -0.09 | 0.07 | 0.02 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | +66.7% | −200.0% | unavailable | unavailable | −71.4% |
| net % | -14.7% | -24.0% | 5.8% | 7.9% | -7.0% | -11.8% | 8.1% | 2.9% |
| Free cash flow | -1.5 m | -3.5 m | -2.9 m | 447.0 k | -4.5 m | -3.1 m | -2.6 m | unavailable |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 1.3 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 14.1 m USD
- Total assets
- 46.5 m USD
- Debt / equity
- unavailable
- Current ratio
- 1.81x
- ROE
- 14.6%
- ROA
- 3.7%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 17.1 m | 29.5 m | 37.3 m | 37.3 m | 52.3 m | 62.1 m | SEC (XBRL)· 31 Mar 2026verified |
| Cost of revenue | 11.1 m | 20.8 m | 29.0 m | 29.5 m | 36.2 m | 46.0 m | SEC (XBRL)· 31 Mar 2026verified |
| Gross profit | 6.0 m | 8.7 m | 8.4 m | 7.8 m | 16.2 m | 16.1 m | SEC (XBRL)· 31 Mar 2026verified |
| Research & development | 1.6 m | 2.2 m | 3.0 m | 3.8 m | 3.8 m | 4.1 m | SEC (XBRL)· 31 Mar 2026verified |
| SG&A | 2.9 m | 3.9 m | 7.6 m | 7.5 m | 7.2 m | 10.4 m | SEC (XBRL)· 31 Mar 2026verified |
| Operating income | 1.5 m | 2.6 m | -2.3 m | -3.5 m | 5.1 m | 1.6 m | SEC (XBRL)· 31 Mar 2026verified |
| Depreciation & amortisation | 358.0 k | 454.0 k | 567.0 k | 742.0 k | 928.0 k | 897.0 k | SEC (XBRL)· 31 Mar 2026verified |
| EBITDA | 1.8 m ≈ | 3.0 m ≈ | -1.7 m ≈ | -2.8 m ≈ | 6.1 m ≈ | 2.5 m ≈ | SEC (XBRL)· 31 Mar 2026derived |
| Interest expense | 496.0 k | 1.2 m | 382.0 k | 838.0 k | 670.0 k | — | SEC (XBRL)· 31 Mar 2025verified |
| Pre-tax income | 989.0 k | 2.4 m | -2.6 m | -4.4 m | 4.5 m | 1.9 m | SEC (XBRL)· 31 Mar 2026verified |
| Income tax | — | 37.0 k | -17.0 k | 6.0 k | 227.0 k | 73.0 k | SEC (XBRL)· 31 Mar 2026verified |
| Net income | 989.0 k | 2.3 m | -2.6 m | -4.4 m | 4.2 m | 1.8 m | SEC (XBRL)· 31 Mar 2026verified |
| Diluted EPS | 0.03 | 0.05 | -0.05 | -0.09 | 0.07 | 0.02 | SEC (XBRL)· 31 Mar 2026verified |
| Weighted average diluted shares | 38.5 m | 47.0 m | 49.1 m | 49.6 m | 65.0 m | 72.6 m | SEC (XBRL)· 31 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 957.0 k | 657.0 k | 2.2 m | 1.7 m | 1.4 m | 1.3 m | SEC (XBRL)· 31 Mar 2026verified |
| Receivables | 2.9 m | 3.9 m | 4.7 m | 3.5 m | 4.9 m | 6.8 m | SEC (XBRL)· 31 Mar 2026verified |
| Inventories | 4.3 m | 6.1 m | 8.8 m | 10.0 m | 20.3 m | 15.0 m | SEC (XBRL)· 19 Aug 2026verified |
| Current assets | 8.8 m | 11.6 m | 16.6 m | 16.3 m | 29.3 m | 25.2 m | SEC (XBRL)· 19 Aug 2026verified |
| Property, plant & equipment, net | 2.9 m | 4.7 m | 7.9 m | 8.7 m | 12.7 m | 14.3 m | SEC (XBRL)· 31 Mar 2026verified |
| Total assets | 13.5 m | 28.4 m | 33.6 m | 32.9 m | 50.0 m | 46.5 m | SEC (XBRL)· 19 Aug 2026verified |
| Accounts payable | 2.1 m | 3.6 m | 6.4 m | 6.3 m | 9.1 m | 4.1 m | SEC (XBRL)· 31 Mar 2026verified |
| Short-term debt | 500.0 k | — | — | — | — | — | SEC (XBRL)· 26 Mar 2021verified |
| Long-term debt | 952.0 k | 1.0 m | 1.0 m | — | — | — | SEC (XBRL)· 29 Mar 2023verified |
| Current liabilities | 6.8 m | 7.3 m | 13.8 m | 15.6 m | 25.8 m | 13.9 m | SEC (XBRL)· 31 Mar 2026verified |
| Equity | 2.7 m † | 7.5 m † | 5.6 m † | 1.9 m † | 10.4 m † | 14.1 m † | SEC (XBRL)· 19 Aug 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -2.1 m | 2.3 m | -1.7 m | -2.0 m | 2.0 m | -8.6 m | SEC (XBRL)· 31 Mar 2026verified |
| Capex | 878.0 k | 1.9 m | 2.8 m | 1.1 m | 4.6 m | — | SEC (XBRL)· 31 Mar 2025verified |
| Free cash flow | -2.9 m ≈ | 447.0 k ≈ | -4.5 m ≈ | -3.1 m ≈ | -2.6 m ≈ | — | SEC (XBRL)· 31 Mar 2025derived |
| Investing cash flow | -878.0 k | -1.9 m | -2.8 m | -1.1 m | -4.6 m | -2.1 m | SEC (XBRL)· 31 Mar 2026verified |
| Financing cash flow | 2.7 m | -747.0 k | 6.0 m | 2.6 m | 2.3 m | 10.6 m | SEC (XBRL)· 31 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 3 of at least 6
- score weight coverage: 18.8% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
05 Nov 2026Source: olivLaw, closing series
Market cap: 61.3 m USD
Key indicators
Coverage and freshness
Score by group
19% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · the input exists, but its latest figure is far older than the latest reported period: not used
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 3 of at least 6; score weight coverage: 18.8% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -3.8% | 33 (vs peers) | 33% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 18.5% | 100 (on a fixed band) | 44% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 1.0x | 14 (on a fixed band) | 22% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial14/100 · 1/3 factors with a value
- Growth· partial100/100 · 1/2 factors with a value
- Quality· partial33/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partialunavailable · 0/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Solesence, Inc. (SLSN). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 62.1 m USD in 2025; YoY growth 18.6%; net margin -3.8%; ROE -15.1%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 3 of at least 6; score weight coverage: 18.8% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Revenue CAGR 3Y: 18.5%
What contradicts it
- Current ratio: 1.0x
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, P/E (TTM), EV/EBITDA, FCF yield, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Perfumes, Cosmetics & Other Toilet Preparations (SIC 2844) · same industry (4-digit SIC) · compared with 15 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| CLColgate-Palmolive Company | 78.5 bn | 38.7 | 358.9% | 9.6% | +1.4% | +23% / +25% |
| KVUEKenvue Inc. | 37.1 bn | 21.9 | 16.3% | 10.9% | −2.1% | +34% / +4% |
| ELFe.l.f. Beauty, Inc. | 6.5 bn | 109.9 | 6.0% | 3.4% | +24.6% | +44% / −7% |
| IPARInterparfums, Inc. | 4.3 bn | 25.5 | 19.5% | 11.3% | +2.5% | +66% / +8% |
| COTYCoty Inc. | 3.4 bn | — | -18.5% | -10.4% | −1.5% | +18% / −66% |
| EPCEdgewell Personal Care Company | 1.3 bn | — | -6.2% | -4.2% | −1.3% | +60% / −18% |
| SLSNSolesence, Inc. | 61.3 m | — | -15.1% | -3.8% | +18.6% | −74% / −7% |
| AXILAxil Brands, Inc. | 35.4 m | 15.5 | 23.3% | 9.3% | +17.5% | +2% / unavailable |
| UGUnited-Guardian, Inc. | 31.2 m | 12.7 | 21.4% | 22.0% | −13.4% | +17% / −16% |
| BNKKBonk, Inc. | 7.8 m | — | -332.4% | -2,330.4% | +201.6% | −84% / −99% |
| CABRCaring Brands, Inc. | 7.8 m | — | -3,889.1% | -183,298.7% | unavailable | −27% / unavailable |
| YCBDcbdMD, Inc. | 4.3 m | — | -40.3% | -13.8% | −1.5% | −37% / −93% |
| YSGYatsen Holding Limited | — | — | -2.7% | -1.9% | +32.2% | −70% / −54% |
| ELEstee Lauder Companies Inc | — | 107.3 | 9.3% | 2.4% | +5.0% | +14% / −16% |
| HLNHaleon plc | — | — | 10.2% | 15.1% | −1.8% | −6% / +7% |
| ODDOddity Tech Ltd | — | 11.3 | 32.6% | 13.7% | +25.2% | −53% / −40% |
1- and 3-year price returns: for SLSN from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Solésence develops skin care products with mineral UV protection and sells active ingredients to other manufacturers, after its revenue grew in 2025 versus the prior year. In the second quarter of 2026 revenue fell to 15.3 million USD and the company reported a net loss of 158 thousand USD, so dependence on a few large customers is an important issue for investors.
SWOT
Strengths
- Proprietary technology with active ingredients and patented formulations gives a differentiation advantage to customers who want products with scientific claims.
- The company grew revenue in 2025 and attracted large customers in consumer products.
- Production infrastructure and compliance processes for regulated products could be leveraged as volumes grow.
Weaknesses
- Dependence on a few large customers makes revenue volatile and sensitive to their ordering decisions.
- Operating cash flow was negative in 2025, and the company relied on loans and financing linked to shareholders.
- Administrative and professional costs rose, and margins remained under pressure in 2026.
Opportunities
- Expanding co-marketing with partner brands and entering high-demand markets could support a new growth cycle.
- Leveraging intellectual property in new formulations could open licensing and development fee revenue.
- If lean efficiency translates into lower costs, margins could recover, especially as volumes rise.
Threats
- A major customer could cancel an order or supply agreement, with a rapid effect on revenue.
- Rising material and labor costs could reduce margins if they cannot be passed on to customers.
- Regulations for cosmetic and pharmaceutical products could become costlier to comply with.
Risks
- Dependence on large customershigh
A small number of customers generate a major part of revenue, and losing one of them could have a significant impact.
- Cash flow and financinghigh
Operating cash flow was negative in 2025, and the company depends on credit lines and loans linked to shareholders.
- Margins under pressuremedium
Production and labor costs have risen, and the ability to pass them on to customers is not assured.
- Accounting corrections and reportingmedium
The company filed late its second quarter 2026 report because of an evaluation of inventory costing allocation methods, which raises questions about internal control.
- Regulation and intellectual propertylow
FDA-regulated products and reliance on patents make the company vulnerable to regulatory changes and litigation.
Investment thesis
What would need to be true (bull case)
- If mineral ingredient technology gains acceptance with new customers, revenue could return to a more stable level.
- Operational efficiency and equipment investments could improve margins as volumes grow.
- Intellectual property could become an advantage for new collaborations with health and beauty brands.
What would break the thesis
- If revenue keeps falling after the peaks from recent launches, quarterly results could remain negative.
- Dependence on a few customers could turn any reduction in orders into a major shock for the business.
- Financing based on loans and shareholder support could limit flexibility if conditions worsen.
What to watch
- Revenue trends by large customer and resumption of ordersQ3 2026
- Gross margin and the effect of lean efficiencyQ3 2026
- Operating cash flow and the level of borrowingsnext 10-K
- Conclusions on inventory costing methodsQ3 2026
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Solésence, Inc. presents itself as a health-oriented, science-driven company focused on skin health, beauty and wellness markets. Its primary products are prestige skin care formulations with mineral-based UV protection enabled by proprietary active pharmaceutical ingredients, which are also sold as ingredients to makers of sunscreens and daily care products. The company keeps legacy lines in advanced materials, such as medical diagnostics and industrial coatings.
Revenue is concentrated in large customers: in 2025 the first customer in consumer products represented 29% of sales, and in the first half of 2026 the main customers accounted for 62% of revenue. Products are made in Bolingbrook, Illinois, where the company leases manufacturing and warehouse space, and production costs have risen with volumes.
In 2026 management focused on operational efficiency, including lean management and selective automation, to protect margins. The second quarter 2026 net loss was also influenced by professional service costs tied to a settlement agreement, which shows the cost structure remains a sensitive area.
Segments
Consumer products (finished formulations)
This is the segment that grew most in 2025, supported by sales to large customers, and also the most volatile. Launches into new distribution channels produced sales peaks, and in 2026 volumes fell after those inventory fills.
Skin care active ingredients
These ingredients, sold to makers of sun and skin care products, are a channel through which the company tries to monetise its own technology. As the large customer in personal care ingredients reduced orders, this segment's contribution to revenue fell in 2026.
Advanced materials and diagnostics
This segment includes legacy coatings, additives and medical diagnostics, which the company considers no longer strategic. Their contribution to revenue is small, and their development affects the whole business more than its direction.
Market context
The market for sun care and mineral UV skin protection is highly competitive, with brands seeking ingredients backed by scientific evidence and transparent formulas. The company describes its offer as integrated into everyday products, placing it between ingredient makers and consumer brands.
Demand in this area depends on the success of large customers and on market acceptance of new products, while in 2026 material and labor costs kept rising. The company says it could offset these increases through efficiency and pricing adjustments, but this depends on contractual terms with customers.
Trends
- Mineral-based sun protectiontailwind
Consumer interest in sun products with mineral ingredients and health claims supports demand for the company's technology, especially for finished formulations sold to partner brands.
- Production cost pressureheadwind
Rising material and labor costs could reduce margins if they cannot be fully passed on to customers, a risk management flagged for 2026.
- Efficiency and automationmixed
Lean management and selective automation could improve margins as volumes grow, if the equipment investments deliver the expected returns.
Competitive position
The company competes with other makers of ingredients and formulations for sun protection and skin care, and its stated advantage lies in patented technology and the ability to integrate into customers' products. Competitive pressure could affect prices and volumes, especially for customers seeking alternatives.
Competition also exists in advanced materials and diagnostics, but the company has stated these lines are no longer strategic. Its competitive position therefore depends mainly on success in skin care products and ingredients.
- Sun protection ingredient makers
Companies that sell UV filters and active ingredients to care brands, competing directly with the company's ingredient line.
- Large sun care and cosmetics brands
Potential customers or competitors in finished formulations, which could develop similar technology in-house.
- Dermatological formula producers
Companies offering skin care with health claims, competing for the same distributors.
- Industrial coatings and additives suppliers
Competitors in the legacy advanced materials lines, where demand is less strategic for the company.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report05 Oct 2026Material agreement · Financial statements and exhibits
- Current report02 Oct 2026Delisting notice · Financial statements and exhibits
- Current report21 Aug 2026Non-reliance on financial statements · Financial statements and exhibits
- Current report20 Aug 2026Results of operations · Financial statements and exhibits
- Quarterly report19 Aug 2026
- Current report10 Jul 2026Material agreement · Financial statements and exhibits
- Quarterly report12 May 2026
- Current report12 May 2026Results of operations · Financial statements and exhibits
- Current report29 Apr 2026Departure or appointment of officers · Financial statements and exhibits
- Annual report31 Mar 2026
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Solésence, Inc. · 31 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Solésence, Inc. · 19 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Solésence, Inc. · 20 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.